<code id='6E6D351C6A'></code><style id='6E6D351C6A'></style>
    • <acronym id='6E6D351C6A'></acronym>
      <center id='6E6D351C6A'><center id='6E6D351C6A'><tfoot id='6E6D351C6A'></tfoot></center><abbr id='6E6D351C6A'><dir id='6E6D351C6A'><tfoot id='6E6D351C6A'></tfoot><noframes id='6E6D351C6A'>

    • <optgroup id='6E6D351C6A'><strike id='6E6D351C6A'><sup id='6E6D351C6A'></sup></strike><code id='6E6D351C6A'></code></optgroup>
        1. <b id='6E6D351C6A'><label id='6E6D351C6A'><select id='6E6D351C6A'><dt id='6E6D351C6A'><span id='6E6D351C6A'></span></dt></select></label></b><u id='6E6D351C6A'></u>
          <i id='6E6D351C6A'><strike id='6E6D351C6A'><tt id='6E6D351C6A'><pre id='6E6D351C6A'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:13611
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

          A Worst CEO gets some much-needed help

          For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

          advertisement

          On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Morgan Health, with ambitious aims, wants you to know it’s still here
          Morgan Health, with ambitious aims, wants you to know it’s still here

          AdobeSANFRANCISCO—Almostthreeyearsago,thecountry’sbiggestbankunveiledaloftyplantofixthehealthcareind

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          Readout Newsletter: Amgen, Regeneron, BGI Group and more

          KristofferTripplaar/SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup toget